Castle Biosciences Receives $6M Credit Facility from Silicon Valley Bank

Castle Biosciences, Inc., a Friendswood, TX-based provider of molecular diagnostics to improve cancer treatment, received a $6m credit facility from Silicon Valley Bank.

The company intends to use the proceeds for commercial and clinical activities aimed at gaining wider adoption of its cutaneous melanoma test, DecisionDx™-Melanoma, as well as support overall operations.

Led by Derek Maetzold, President and CEO, Castle Biosciences is a molecular diagnostics company that offers tests for patients with uveal melanoma, cutaneous melanoma and esophageal cancer, among others.
It has laboratory operations in Phoenix, AZ.



Join the discussion